Загрузка...
Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma
The anti-CD20 antibody rituximab has substantially improved outcomes in patients with B-cell non-Hodgkin lymphomas. However, many patients are not cured by rituximab-based therapies, and overcoming de novo or acquired rituximab resistance remains an important challenge to successful treatment of B-c...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2854431/ https://ncbi.nlm.nih.gov/pubmed/20139095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-10-250555 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|